Atossa Therapeutics, Inc. (ATOS) Stock Analysis & Investment Frameworks
Atossa Therapeutics, Inc. (ATOS) stock analysis on Invetso. Review Atossa Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Atossa Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Atossa Therapeutics, Inc. Key Financial Metrics
- Market Cap: $25.25M
- Revenue: $N/A
- ROE: -102.99%
- ROIC: -146.30%
- Dividend Yield: N/A
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Atossa Therapeutics, Inc. Investment Frameworks
Invetso analyzes Atossa Therapeutics, Inc. (ATOS) across the following frameworks:
- Atossa Therapeutics, Inc. 10Y Growth Potential
- Atossa Therapeutics, Inc. Scenario Analysis
- Atossa Therapeutics, Inc. Risks & Opportunities
- Atossa Therapeutics, Inc. Economic Moat
- Atossa Therapeutics, Inc. Business Model
- Atossa Therapeutics, Inc. Management
- Atossa Therapeutics, Inc. SWOT Analysis
- Atossa Therapeutics, Inc. Porter's 5 Forces
- Atossa Therapeutics, Inc. PESTLE Analysis
- Atossa Therapeutics, Inc. ESG Analysis